---
document_datetime: 2023-09-21 21:21:17
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hetlioz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: hetlioz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.2361244
conversion_datetime: 2025-12-18 23:13:05.548297
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Hetlioz

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0032/G          | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - | 10/10/2022                          |                                             | SmPC, Annex II, Labelling and PL |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                           |            |            |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| IB/0030             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                  | 31/08/2022 |            | SmPC                              |
| IB/0029             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                     | 14/03/2022 | n/a        |                                   |
| PSUSA/10394 /202107 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                                                                                                                  | 10/02/2022 | n/a        | PRAC Recommendation - maintenance |
| IA/0027             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 04/10/2021 | n/a        |                                   |
| PSUSA/10394 /202101 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                                                                                                                  | 02/09/2021 | n/a        | PRAC Recommendation - maintenance |
| IAIN/0026           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing     | 11/06/2021 | 01/07/2022 | Annex and PL                      |

<div style=\"page-break-after: always\"></div>

| IAIN/0025           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                        | 22/04/2021   | n/a        |                        |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IA/0023/G           | This was an application for a group of variations. B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 25/02/2021   | n/a        |                        |                                   |
| IAIN/0022           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                | 15/02/2021   | n/a        |                        |                                   |
| PSUSA/10394 /202007 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/02/2021   | n/a        |                        | PRAC Recommendation - maintenance |
| T/0020              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/08/2020   | 17/09/2020 | SmPC, Labelling and PL |                                   |
| PSUSA/10394 /202001 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                                                                                                                                                                                                                                                                                                                                                                         | 03/09/2020   | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| R/0018              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                              | 30/04/2020   | 03/07/2020   | SmPC and PL     | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Hetlioz in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10394 /201907 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                                                                                                                                                                                                                                                                                                                                            | 16/01/2020   | n/a          |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| PSUSA/10394 /201901 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                                                                                                                                                                                                                                                                                                                                            | 11/07/2019   | n/a          |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| IAIN/0016/G         | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 01/04/2019   | n/a          |                 |                                                                                                                                                                                                                                                                         |
| IAIN/0014/G         | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                  | 29/03/2019   | 28/02/2020   | Annex II and PL |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                     | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing              |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0013              | Transfer of Marketing Authorisation                                                                                                           | 19/12/2018 | 25/02/2019 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUSA/10394 /201807 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                     | 17/01/2019 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10394 /201801 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                     | 12/07/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10394 /201707 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                     | 11/01/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10394 /201701 | Periodic Safety Update EU Single assessment - tasimelteon                                                                                     | 06/07/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0008             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 06/07/2017 | 01/12/2017 | SmPC                   | Data presented showed that the concomitant administration of tasimelteon with inducers or inhibitors of CYP2C19 is not expected to alter plasma concentrations or exposure of tasimelteon or its metabolites in a clinically meaningful way. Therefore a healthy volunteer study to investigate the CYP2C19 Drug-Drug Interaction potential is not needed. Caution should be used when administering Hetlioz in combination with fluvoxamine or other strong CYP1A2 inhibitors, particularly those which also inhibit other enzymes involved in the clearance of Hetlioz because of a potentially large increase in tasimelteon exposure and |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                               |            |     | greater risk of adverse reactions. CYP1A2 and CYP3A4 are enzymes identified to play a role in the metabolism of tasimelteon, with a minor role for CYP2C9/C19. Medicinal products that inhibit CYP1A2 and CYP3A4 have been shown to alter the metabolism of tasimelteon in vivo. Caution should be used when administering tasimelteon in combination with fluvoxamine or other strong CYP1A2 inhibitors such as ciprofloxacin and enoxacin because of a potentially large increase in tasimelteon exposure and greater risk of adverse reactions: the AUC0-inf and Cmax of tasimelteon increased by 7-fold and 2-fold, respectively, when co-administered with fluvoxamine 50 mg (after 6 days of fluvoxamine 50 mg per day). This is deemed even more important for strong CYP1A2 inhibitors also inhibiting other enzymes involved in the clearance of HETLIOZ (e.g. fluvoxamine and ciprofloxacin). Tasimelteon is extensively metabolised. Metabolism of tasimelteon consists primarily of oxidation at multiple sites and oxidative dealkylation resulting in opening of the dihydrofuran ring followed by further oxidation to give a carboxylic acid. CYP1A2 (35.4%) and CYP3A4 (24.3%) are the major enzymes identified to play a role in the metabolism of tasimelteon. CYP2C9 (18.8%) and CYP2C19 (15.1%) also contribute to the metabolism of tasimelteon. Tasimelteon clearance does not appear to be affected by   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 23/03/2017 | n/a | In order to address concerns regarding the phototoxicity potential of tasimelteon and its main metabolites, the Marketing Authorisation Holder (MAH) has submitted three in vitro studies in fulfilment of post authorisation measure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     |                                                                            |            |            |                        | MEA 004. First, the MAH conducted a study to determine the molar extinction coefficient for tasimelteon and its main metabolites (Study VCR-TMI-121012). Molar extinction coefficient (MEC) values for metabolites M3, M12, and M13 were above 1000 L/mol/cm. Therefore, further testing was undertaken with these metabolites in an in vitro phototoxicity test as recommended by the ICH Guideline S10. Subsequently two studies were conducted to assess the phototoxicity potential of tasimelteon ' s metabolites M12, M14, and M3 (TAJ0044 and TAJ0045). The results of the in vitro tests indicated that metabolites M3, M12 and M14 do not show phototoxic potential in the UVA range of 315 - 380 nm. However, the findings were limited to the UVA range as the metabolites absorb at approximately 290 nm which is below the threshold of compounds that warrant phototoxicity testing, metabolites (in-line with ICH Guidance S10) generally do not warrant separate photosafety assessments, as metabolism does not typically result in chromophores that are substantially different from those in the parent molecule and there have been no phototoxic signals seen in patients in the post-marketing data collected so far. No further phototoxicity testing is required.   |
|---------------------|----------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10394 /201607 | Periodic Safety Update EU Single assessment - tasimelteon                  | 12/01/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IAIN/0006           | A.1 - Administrative change - Change in the name and/or address of the MAH | 21/12/2016 | 01/12/2017 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUSA/10394         | Periodic Safety Update EU Single assessment -                              | 02/09/2016 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| /201601   | tasimelteon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     |                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------|
| II/0003/G | This was an application for a group of variations. Submission of: -In vitro pharmacokinetic study XT154077-category 3 study in the RMP in order to fulfil MEA 009. -In vitro pharmacokinetic study XT154076 -category 3 study in the RMP in order to fulfil MEA 010. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission authority | 26/05/2016 | n/a | of studies to the competent |
| II/0002   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 19/11/2015 | n/a |                             |
| II/0001   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 19/11/2015 | n/a |                             |